Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

Sun, Hairui; Yin, Lianhu; Li, Showwei; Han, Song; Song, Guanbin; Liu, Ning; Chen, Yan

doi:10.1007/s11060-013-1107-5

Cited by 70 publications

(38 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the survival analysis, previous studies demonstrated the prognostic significance of IDH1 mutations (Arita et al., 2015; Brennan et al., 2013; Ducray et al., 2011; Hartmann et al., 2010; Killela et al., 2014; Lewandowska et al., 2014; Mellai et al., 2011; Olar et al., 2012; Parsons et al., 2008; Polivka et al., 2014; Sanson et al., 2009; Shibahara et al., 2011; Sun et al., 2013; Takano et al., 2012; Weller et al., 2009). Some authors observed that OS and PFS in IDH mutated cases were about twice longer than in wild‐type patients (Arita et al., 2015; Polivka et al., 2014), and others showed that mutation in IDH1 was an independent factor for a favorable prognosis (Brennan et al., 2013; Ducray et al., 2011; Polivka et al., 2014; Sanson et al., 2009; Shibahara et al., 2011).…”

Section: Discussionmentioning

confidence: 99%

Genetic alterations of IDH1 and Vegf in brain tumors

et al. 2017

View full text Add to dashboard Cite

BackgroundThis study evaluates the presence of R132H mutation in isocitrate dehydrogenase (IDH1) gene and the vascular endothelial growth factor (VEGF) +936 C/T polymorphism in brain tumors. The impact of these genetic alterations on overall survival (OS) and progression free survival (PFS) was evaluated.MethodsA cohort of 80 patients surgically treated at Hospital Clínico San Carlos, Madrid, between March 2004 and November 2012, was analyzed. Tumors were distributed in 73 primary brain tumors (gliomas, meningiomas, hemangiopericytomas and hemangioblastomas) and seven secondary tumors evolved from a low grade glioma, thus providing a mixed sample.Results IDH1 R132H gene mutation was found in 12 patients (15%) and appears more frequently in secondary tumors (5 (71.4%) whereas in 7 (9.7%) primary tumors (p < .001)). The mutation is related to WHO grade II in primary tumors and a supratentorial location in secondary tumors. The OS analysis for IDH1 showed a tendency towards a better prognosis of the tumors containing the mutation (p = .059).The IDH1 R132H mutation confers a better PFS (p = .025) on primary tumors. The T allele of VEFG +936 C/T polymorphism was found in 16 patients (20%). No relation was found between this polymorphism and primary or secondary tumor, neither with OS or PFS.Conclusions IDH1 R132H gene mutation is exclusive in supratentorial tumors and more frequent in secondary ones, with a greater survival trend and better PFS in patients who carry it. The T allele of VEGF +936 C/T polymorphism is more common in primary tumors, although there is no statistical relation with survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic alterations of IDH1 and Vegf in brain tumors

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The prognostic factors predicting survival of gliomas patients can help us not only get a better understanding of the pathogenesis of brain tumors but provide much help in choosing optimal treatment for patients. Currently, there are a number of biomarkers identified as prognostic factors in brain tumors, such as isocitrate dehydrogenase mutations and matrix metalloproteinase 9 expression [30][31][32][33][34].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis

Liao²,

Guo

et al. 2015

Mol Neurobiol

View full text Add to dashboard Cite

Many studies have shown that microRNAs have important roles in the development and progression of various cancers. Recent studies also showed that microRNA-21 expression may be associated with the prognosis of patients with several common cancers. However, there was still lack of evidence for the prognostic role of microRNA-21 expression in brain tumors. We performed a systemic review and meta-analysis of published and unpublished studies to assess the prognostic role of microRNA-21 expression in patients with brain tumors. PubMed, Embase, and Google Scholar databases were searched for eligible studies with data assessing the prognostic role of microRNA-21 expression in brain tumors. Pooled hazard ratios (HRs) of microRNA-21 expression for overall survival and 95% confidence intervals (CI) were calculated. Six studies from five publications were finally included into the meta-analysis. Those six studies included a total of 747 patients with brain tumors and 654 patients with gliomas. For overall survival, the pooled HR of higher microRNA-21 expression in patients with brain tumors was 1.82 (95% CI 1.29-2.58, P = 0.001). In patients with gliomas, the HR for overall survival of higher microRNA-21 expression was 1.83 (95% CI 1.09-3.09, P = 0.023). Sensitivity analysis by omitting one study by turns also showed there was no obvious influence of individual study on the pooled HRs. There was no obvious risk of publication bias in the meta-analysis. The present meta-analysis suggests that microRNA-21 is associated with the prognosis of patients with brain tumors, and high expression of microRNA-21 can predict poor prognosis in patients with brain tumors.

show abstract

“…33 This strong association between LGGs and IDH mutation has several diagnostic implications. The first is the plausible hypothesis that IDH1-mutant GBMs represent malignant transformation of undiagnosed LGGs, and IDH1 wild-type GBM is, in many ways, a different disease sharing the same histological features.…”

Section: Diagnostic and Prognostic Implications Of Idh Mutationmentioning

confidence: 99%

“…A meta-analysis of 937 patients showed that among patients with LGG, those whose lesions had IDH mutation had a more favorable prognosis (pooled hazard ratio [HR] of 0.585, p = 0.025) compared with IDH wild-type LGGs. 33 In the NOA-04 trial of 318 patients with anaplastic glioma, multivariate analyses also showed that IDH1 mutation was an independent prognostic factor that conferred a longer progression-free survival (PFS) irrespective of the treatment received, and this effect was statistically greater than the risk reduction seen with 1p19q codeletion, MGMT promoter methylation, or histological features. 39 Conversely, the absence of IDH mutation in an intermediate-or even low-grade glioma portends a potentially worse prognosis than that of a GBM that has IDH mutation.…”

Section: Diagnostic and Prognostic Implications Of Idh Mutationmentioning

confidence: 99%

“…39 Conversely, the absence of IDH mutation in an intermediate-or even low-grade glioma portends a potentially worse prognosis than that of a GBM that has IDH mutation. 33 Codeletion of 1p19q and MGMT promoter methylation are also independent markers of a favorable prognosis that appear to increase the sensitivity of tumors to radiation and chemotherapy. 39 Silencing of the MGMT promoter by methylation has been shown in prior trials to benefit patients with GBM who receive treatment with temozolomide.…”

Section: Diagnostic and Prognostic Implications Of Idh Mutationmentioning

confidence: 99%

See 1 more Smart Citation

Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas

Chen

Ravindra

Cohen

et al. 2015

FOC

View full text Add to dashboard Cite

The preferred management of suspected low-grade gliomas (LGGs) has been disputed, and the implications of molecular changes for medical and surgical management of LGGs are important to consider. Current strategies that make use of molecular markers and imaging techniques and therapeutic considerations offer additional options for management of LGGs. Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes suggest a role for this abnormal metabolic pathway in the pathogenesis and progression of these primary brain tumors. Use of magnetic resonance spectroscopy can provide preoperative detection of IDH-mutated gliomas and affect surgical planning. In addition, IDH1 and IDH2 mutation status may have an effect on surgical resectability of gliomas. The IDH-mutated tumors exhibit better prognosis throughout every grade of glioma, and mutation may be an early genetic event, preceding lineage-specific secondary and tertiary alterations that transform LGGs into secondary glioblastomas. The O6-methylguanine-DNAmethyltransferase (MGMT) promoter methylation and 1p19q codeletion status can predict sensitivity to chemotherapy and radiation in low- and intermediate-grade gliomas. Thus, these recent advances, which have led to a better understanding of how molecular, genetic, and epigenetic alterations influence the pathogenicity of the different histological grades of gliomas, can lead to better prognostication and may lead to specific targeted surgical interventions and medical therapies.

show abstract

Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

Cited by 70 publications

References 43 publications

Genetic alterations of IDH1 and Vegf in brain tumors

Genetic alterations of IDH1 and Vegf in brain tumors

Prognostic Role of microRNA-21 Expression in Brain Tumors: a Meta-analysis

Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas

Contact Info

Product

Resources

About